Sleuth vs. Evaluate Pharma

See every analyst behind the consensus

Evaluate averages analysts’ models into one consensus number. Sleuth puts each analyst’s estimate, price target, and note side by side, on top of the drugs, trials, companies, and deals you’d look up in Evaluate.

Sleuth gives you the database for free, with analytical capabilities on top

Every Sleuth plan comes with the drugs, trials, companies, and deals you’d look up in Evaluate. Sleuth then builds the analysis for your question from them.

Choose Sleuth for

Landscapes, partner and asset screens, deal comps, and each analyst’s view behind a forecast.

Keep Evaluate if

Your team builds financial models every day on its consensus forecasts.

Start at $249 a month instead of $20K+ a year

A database subscription

$20K+ a year

The database alone. The analysis is still on you.

Sleuth

From $249 a month

Everything your database has, plus 3,000 credits a month.

See every plan

How Sleuth and Evaluate Pharma compare

Sleuth

Evaluate Pharma

The database

Sleuth

Included in every plan: drugs, trials, companies, and deals in one knowledge base. Browsing is free and doesn’t use credits.

Evaluate Pharma

A yearly license for the datasets you choose, quoted for your team, with no published price.

Your columns

Sleuth

The standard fields, plus any column you ask for. Ask “who holds the rights outside the US?” and Sleuth adds it as a column, filled in for every program.

Evaluate Pharma

The same fields for every subscriber. A criterion it doesn’t track can’t be added, so you rank against the fields it has.

Sources

Sleuth

Click any value to see the filing, registry entry, or broker note behind it, with its date, a confidence score, and whether it’s sourced, inferred, or unknown. Sleuth flags the few cells worth checking.

Evaluate Pharma

You check the records yourself. Its AI assistant cites Evaluate’s own record, not the filing or note behind it.

Analysts’ views

Sleuth

Each analyst’s estimate, price target, and note side by side, from 35+ research providers.

Evaluate Pharma

One consensus number per drug, averaged from analysts’ models.

AI

Sleuth

Sleuth reads filings, registries, and sell-side research to build the columns needed to answer your question, then the analysis on top.

Evaluate Pharma

Its AI assistant answers from the same fixed fields as the database.

Keeping it current

Sleuth

Turn on monitoring, and the dataset updates as trials, filings, and deals come in, with a change log and earlier versions kept.

Evaluate Pharma

You pull the data again each time you need it current.

In Claude, ChatGPT, and Copilot

Sleuth

In every plan. Sleuth builds the analysis from the chat and saves the project to your account.

Evaluate Pharma

Using Evaluate data in your own AI tools takes a separate license.

Forecasts and valuation

Sleuth

Analysts’ estimates and price targets, each linked to its note, for a first pass on sizing and comps.

Evaluate Pharma

A standardized consensus series back to 2003, sales by indication, and its own risk-adjusted valuations.

Every analyst’s estimate, side by side

Evaluate gives you one consensus number for each drug. Sleuth reads the notes from 35+ providers and lines up each analyst’s estimate, price target, and reasoning, with a link to the note.

See the whole range

Each analyst’s estimate gets its own row, so you can see how wide the spread is and who sits at each end.

Read the reasoning

Each view comes with the analyst’s stance, main risk, and a link to the note, so you can tell a bull case from a bear case.

Check it against the data

Sleuth puts the forecasts next to the trials, readouts, and deals for the same program.

Chinese and private programs, in the same landscape

Evaluate publishes consensus forecasts for almost 6,000 drugs, so most of the early, private, and Chinese programs you’re looking at have no forecast at all. Sleuth has those programs, including about 22,000 from China, read in Chinese.

~22,000

Chinese programs

From China’s registries and filings, read in Chinese

400K+

Companies

Public and private, with Chinese and English names

300K+

Patents

Where early programs often show up first

150K+

Drugs

Every program by target, modality, and phase

Sleuth knowledge base, November 2026.

Answers built from the documents behind the records

Evaluate says its AI assistant’s answers “come exclusively from the licensed datasets,” so it can only tell you what’s already in Evaluate’s fields. Sleuth reads the filings, registry entries, and analyst notes behind each record, in Studio or in Claude, ChatGPT, and Copilot.

When to keep Evaluate

Keep Evaluate if your team builds financial models every day on its consensus forecasts. For a first pass on sizing and comps, Sleuth has each analyst’s estimate and price target, linked to its note.

Models on one standard series

You update your models against a consensus your bankers and board already use.

Comparisons back to 2003

You check today’s forecasts against consensus history going back years.

Its valuations on every asset

You need its risk-adjusted value on each asset, private ones included.

Questions about moving from Evaluate Pharma

Can Sleuth replace Evaluate Pharma?

For pipeline, landscape, and deal work, yes: asset screens, competitive landscapes, partner searches, and deal comps. Every plan includes the drugs, trials, companies, and deals you’d look up in Evaluate, and Sleuth builds the analysis on top. Keep Evaluate if your team builds financial models every day on its consensus forecasts.

What does every Sleuth plan include?

Analysis built for your question, a knowledge base of drugs, trials, companies, and deals, and searchable documents, including sell-side research from 35+ providers. Browsing the knowledge base and reading the research are free. You can try all of it free for 14 days.

Does Sleuth have consensus sales forecasts?

Sleuth shows each analyst’s estimate, price target, and note side by side, so you can see the range and the reasoning. It doesn’t keep a standardized consensus series the way Evaluate does. Keep Evaluate if your team builds financial models every day on its consensus forecasts.

Does Evaluate Pharma have AI?

Yes. Its AI assistant’s answers “come exclusively from the licensed datasets,” and each one cites the Evaluate record behind it. Sleuth also reads the filings, registries, and analyst notes behind the records, and links each value to the document it came from.

How does Sleuth’s coverage compare with Evaluate’s?

Every plan includes the drugs, trials, companies, and deals you’d look up in Evaluate. Where Sleuth goes further is China: about 22,000 programs, read in Chinese. Start the free trial and run your own question to compare.

Can I use Sleuth in Claude, ChatGPT, or Copilot?

Yes, on every plan. Connect Sleuth, and it builds the analysis from the chat, with a source on every value, and saves each project to your Sleuth account. Using Evaluate data in your own AI tools takes a separate license: in Evaluate’s words, “licensing options are available for organizations looking to integrate Evaluate data into AI-enabled systems and applications.”

Bring the question you’d take to Evaluate

Set up in Claude, ChatGPT, or Copilot